WASHINGTON (Reuters) – An unrelenting U.S. coronavirus surge pushed besieged hospitals further to the brink as the United States pressed on with its immunization rollout on Thursday and prepared to ship nearly 6 million doses of a new vaccine on the cusp of winning regulatory approval.
A healthcare worker draws the coronavirus disease (COVID-19) vaccine from a vial at Martin Luther King Jr. Community Hospital, in South Los Angeles, California, U.S., December 17, 2020. REUTERS/Lucy Nicholson
COVID-19 hospitalizations rose to record heights for a 19th straight day, with nearly 113,000 coronavirus patients counted in U.S. medical facilities nationwide on Wednesday, while 3,580 more perished, the most yet in a single day.
The virus has claimed over 311,000 lives in the United States to date, and health experts have warned of a deepening crisis this winter as intensive care units (ICUs) fill up and hospital beds spill over into hallways.
“We expect to have more dead bodies than we have spaces for them,” Los Angeles Mayor Eric Garcetti said at a briefing on Thursday, adding that the country’s second-largest city had fully exhausted its ICU capacity.
The number of U.S. cases rose by at least 239,018 on Thursday, according to a Reuters tally, the highest one-day increase since the pandemic began, driving the number of known infections nationally to more than 17 million.
The tolls mounted as U.S. regulators weighed whether to grant emergency use authorization for a vaccine developed by Moderna Inc, just a week after an earlier vaccine from Pfizer Inc and German partner BioNTech SE won consent for mass distribution.
A panel of outside advisers to the U.S. Food and Drug Administration overwhelmingly endorsed Moderna’s vaccine candidate for emergency use after a daylong meeting on Thursday.. FDA authorization could come as soon as Friday.
Both vaccines require two doses, given three or four weeks apart, for each person inoculated.
The initial 2.9 million doses of the Pfizer/BioNTech vaccine began shipping on Sunday and were still making their way to hospitals across the country and into the arms of doctors, nurses, and other frontline medical professionals.
Slideshow ( 4 images )
Some of the first shots were also going to residents and staff of long-term care facilities. Other essential workers, senior citizens and people with chronic health conditions will be next on the list.
BEDS IN CORRIDORS
It will take several months before vaccines are widely available to the public on demand, and opinion polls have found many Americans are hesitant about getting inoculated.
Some are distrustful of immunizations in general, and some are wary of the unprecedented speed with which the first vaccines were developed and rolled out – 11 months from the first documented U.S. cases of COVID-19.
Health authorities have sought to reassure Americans that large-scale clinical trials and rigorous scientific review found the vaccines to be safe as well as highly effective at preventing illness.
Those messages have been combined with urgent pleas for Americans to remain diligent about social distancing and mask-wearing until immunizations become widely available.
Data shows infections continuing to spread virtually unabated across much of the country, apparently fueled by increased transmissions of the virus as many Americans disregarded warnings to avoid social gatherings and unnecessary travel over the Thanksgiving holiday last month.
California has been hit particularly hard in recent weeks, with many of its hospitals reporting ICUs at or near capacity, a dire situation that triggered a renewal of sweeping stay-at-home orders across much of the state.
“Hospitals and healthcare workers continue to be stretched to the limit, as we continue to surge beyond even what we anticipated. And we’re not even through the holidays yet,” said Adam Blackstone, a spokesman for the Hospital Association of Southern California.
In San Bernardino County, where available ICU space was down to zero, newly admitted patients at Arrowhead Regional Medical Center were lined up in beds in corridors waiting for care, spokeswoman Justine Rodriguez told Reuters.
With the strain taking a growing toll on medical staff, the race to expand vaccinations is seen as critical to preventing a collapse of healthcare systems.
Health and Human Services Secretary Alex Azar told CNBC on Thursday that 5.9 million Moderna vaccine doses had been allotted for state governments to receive and were ready to distribute nationwide starting at the weekend.
The Moderna vaccine has less onerous cold storage requirements than the Pfizer/BioNTech shot, making it a better option for remote and rural areas.
Nevertheless, ambivalence over the vaccine has emerged even among pockets of healthcare workers designated as first in line for inoculation.
“Some are on the fence. Some feel that we need to get it done. It’s split down the middle,” Diego Montes Lopez, 28, a phlebotomist at Martin Luther King Jr. Community Hospital in South Los Angeles, said of co-workers after getting injected himself.
But Dr. Simon Mates, an ICU co-medical director at Dignity Health California Hospital Medical Center in downtown Los Angeles, said the physicians and nurses he knows view the vaccine as having arrived at a crucial moment.
“Our biggest concern was: ‘What if one of us gets sick?’ But now with the vaccine, that concern seems to be ebbing,” said Mates, who learned Wednesday that he had already received the vaccine, rather than a placebo, as a participant in the Pfizer trials. “It’s one less thing to worry about.”
Reporting by Susan Heavey, Sharon Bernstein, Dan Whitcomb, Manas Mishra, Peter Szekely, Richard Cowan, Susan Cornwell, Lucy Nicholson and Anurag Maan; Writing by Daniel Trotta and Steve Gorman; Editing by Steve Orlofsky, Bill Berkrot, Grant McCool and Richard Pullin
TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.
The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.
“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.
The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.
But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.
Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.
“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.
“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”
Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.
The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.
In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.
Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.
The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.
The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.
Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.
Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.
It will also re-evaluate its design ranks.
Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.
Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.
This report by The Canadian Press was first published Sept. 13, 2024.
VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.
No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.
About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.
Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.
Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.
A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”
This report by The Canadian Press was first published Sept. 12, 2024.
MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.
The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.
The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.
Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.
On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.
Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.
This report by The Canadian Press was first published Sept. 12, 2024.
